• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

September 23, 2019
Company Drug/Device Medical Condition Status
Clover Biopharmaceuticals, Inc. SCB-313 peritoneal carcinomatosis Phase 1 trial initiated enrolling subjects in China
Immunic IMU-935 various inflammatory and autoimmune diseases Phase 1 trial initiated
Benitec Biopharma BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Phase 1 trial initiated
Transgene TG4050 HPV negative, squamous cell carcinoma of the head and neck (SCCHN) Phase 1 trial initiated enrolling subjects that have received an adjuvant (first line) therapy in the UK and France
Transgene TG4050 ovarian cancer Phase 1 trials initiated enrolling subjects after first-line surgery and chemotherapy in France and the U.S.
Poxel SA PXL065 Non-alcoholic steatohepatitis (NASH) Phase 1b trial initiated enrolling 30 healthy subjects
Applied Molecular Transport AMT-101 Ulcerative Colitis Phase 1b trial initiated enrolling 20 adult subjects in Europe
NOXXON NOX-A12 in combination with radiotherapy Brain cancer Phase 1/2 trial recruiting newly diagnosed patients with brain tumors who would not benefit from the current standard of care of chemoradiotherapy and whose tumors cannot be fully resected by surgery in Germany
REVOLUTION Medicines RMC-4630 in combination with cobimetinib (Cotellic) relapsed/refractory solid tumors harboring specific genomic mutations Phase 1b/2 trial initiated
Momotaro-Gene MTG201 in combination with PD-1 inhibitor nivolumab (Opdivo) relapsed malignant pleural mesothelioma Phase 2 trial initiated enrolling 12 subjects with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy at Baylor College of Medicine in Houston, Texas
Pulmatrix Pulmazole Allergic Bronchopulmonary Aspergillosis (ABPA) Phase 2 trial initiated enrolling 64 subjects with asthma
Graybug Vision, Inc. GB-102 macular edema (ME) secondary to Diabetic Macular Edema (DME) or Retinal Vein Occlusion (RVO) Phase 2a trial initiated enrolling 20 subjects at six centers in the U.S.
Alnylam Pharmaceuticals, Inc. patisiran transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy Phase 3 study initiated enrolling 300 adult subjects with ATTR amyloidosis (hereditary or wild type) with cardiomyopathy
Apollo Endosurgery, Inc. Polypropylene Suture-Anchor Assembly pass and anchor suture in the gastrointestinal tract 510(k) Clearance granted by the FDA
Janssen Erleada metastatic castration-sensitive prostate cancer (mCSPC) Supplemental New Drug Application granted by the FDA

Merck

Eisai

Keytruda in combination with Lenvima advanced endometrial carcinoma Approval granted by the FDA
Xeris Pharmaceuticals GVOKE (glucagon) injection severe hypoglycemia Approval granted by the FDA

 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing